SynthesisInternational ophthalmology2025
Outcomes of Baerveldt implantation for pediatric glaucoma following surgery: a systematic review and meta-analysis.
Synthesis in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric glaucoma following surgery (GFS) remains a serious postoperative complication with potential for vision loss. Although glaucoma drainage devices are widely used in this setting, high-quality pooled evidence on the Baerveldt glaucoma implant (BGI) in children is limited. To systematically evaluate the efficacy and safety of BGI in pediatric patients with GFS.
methodsFollowing PRISMA guidelines, five databases were searched up to August 2025. Eligible studies included pediatric cohorts (≤ 18 years) undergoing BGI after surgery, reporting intraocular pressure (IOP) outcomes or surgical success. Data were pooled using random-effects meta-analysis.
resultsFive studies (116 patients) met inclusion criteria. The mean age ranged from 3.0-7.8 years, with average follow-up of 31 months. The pooled success rate of IOP control was 84.5% (95% CI 0.75-0.91), with no evidence of heterogeneity. Hypotony occurred in 7.5%, choroidal effusion in 9%, and rare events included phthisis bulbi (2%), endophthalmitis (1.4%), and corneal decompensation (3.3%).
conclusionBGI provides effective and relatively safe IOP control after surgery, with complication rates comparable to or lower than alternative surgical options. However, the current evidence is limited by small sample sizes, retrospective study designs, and short- to mid-term follow-up. Long-term, multicenter prospective studies are needed to better define its long-term safety and efficacy.
Indexed as
Identifiers
41364272What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.